Business Wire

ESHOPWORLD

Share
eShopWorld Appoints Martim Avillez Oliveira as Chief Commercial Officer - EMEA and APAC

eShopWorld (ESW), the leading cross-border ecommerce technology and services provider, today announces the appointment of Martim Avillez Oliveira as Chief Commercial Officer, EMEA and APAC.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20210412005546/en/

Oliveira is a former Executive Vice President at global supply chain and logistics specialist, Li & Fung, has 15 years of industry experience in retail and global sourcing, having worked with the world’s leading fashion brands and retailers, including Inditex, Marks & Spencer, J.Crew and Galeria Karstadt Kaufhof, managing end-to-end supply chains.

In his new role, Oliveira will drive forward ESW’s strategic growth and development with a focus on crafting routes to market within and between the EMEA and APAC that enable retailers and brands to meet the huge latent demand for direct-to-consumer (D2C) engagement in these territories. Oliveira previously served as a member of ESW’s Retail Advisory Council, providing strategic guidance and amplifying the company’s cross-border ecommerce proposition globally.

“2020 saw historic growth in year-on-year cross-border ecommerce sales and reinforced the importance of international ecommerce for the retail industry as an enabler to meet customer demand at its point of origin while mitigating against fluctuations in local markets,” said Tommy Kelly, CEO of ESW.

“ESW saw significant growth in demand from consumers in Asian countries, with the Philippines in particular being one of the fastest growing global markets last year for brands and retailers using our technology and services to sell internationally. Martim’s insights, expertise and relationships across both APAC and the EMEA will allow us to expand our reach in these territories, whose emerging middle class will be a significant driver of global demand for Western brands within a short period of time. As a member of the ESW Advisory Council, Martim has already had a significant role in realising our global expansion strategy in these markets and we are very excited to formally welcome him as part of our global leadership team during this time of unprecedented opportunity.”

During his time at Li & Fung, Oliveira, who lived in Hong Kong for 10 years, held full P&L responsibility for business units to excess of $800 million cost of goods and achieved a strong track record of generating year-on-year growth and revenue. He also coordinated the group business development activities in Europe and the US.

“The events of last year have clearly shown retail brands need to mitigate risks, diversify and balance their distribution to thrive. As home to eight of the world's ten largest megacities, Asia, which has a growing digitally native middle class in all countries who are brand and status hungry, offers enormous expansion opportunities for both established heritage and emerging disruptor brands,” commented Oliveira.

“But many of these brands don’t have the digital capabilities, local expertise or capital required to fully leverage international opportunities and, while it may be tempting to look toward marketplaces as a route to these markets, we know the highest value cross-border shoppers want to engage with and buy directly from brands. ESW offers a seamless end-to-end solution that helps brands capitalise on this golden era for direct-to-consumer, cross-border ecommerce.”

Oliveira concluded: “Having been at the forefront of design, product development, global sourcing and production management, ESW represents the next mile in the journey. It’s the upstream part of the chain, moving from physical to digital, focusing on getting goods to international markets, looking at the most cost-effective route and solutions, while delivering fully localised shopping experiences to consumers around the world.”

In addition to his role at ESW, Oliveira is also non-executive and an advisor to Tiger Chark, a New York based strategic Advisory firm, and a member of the board of the Portuguese - Hong Kong Chamber of Commerce and Industry.

Ends

Notes to Editors

About eShopWorld:
ESW is the cross-border ecommerce leader, empowering the world’s best-loved brands and retailers to make global shopping better, safer, simpler and faster, end-to-end. From compliance, data security, fraud protection, taxes, and tariffs to checkout, delivery, returns, customer service, and demand generation, our powerful combination of technology and human ingenuity covers the entire shopper journey across 200 markets.

Methodology:
ESW’s latest consumer survey was fielded from more than 22,000 consumers in 11 countries (Australia, Canada, Chile, France, Germany, Mexico, Russia, Singapore, Turkey, the UK and the US), who were surveyed online in December 2020. Gen Zers are defined as consumers ages 18–24, Millennials as ages 25–40, Gen Xers as ages 41–56, Baby Boomers as ages 57–75 and the Silent generation as ages 76–92. To gauge how Baby Boomers’ global online shopping preferences differ from those of Gen Zers and millennials (shoppers ages 40 and under), ESW looked specifically at survey responses from shoppers in seven countries: Australia, Canada, France, Germany, Russia, the UK and the US.

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

Incyte Announces Phase 1 Results for its TGFβR2×PD-1 Bispecific Antibody in Advanced Colorectal Cancer and KRAS G12D Inhibitor in Advanced Pancreatic Ductal Adenocarcinoma19.10.2025 19:30:00 CEST | Press release

Data presented at ESMO 2025 show INCA33890, a TGFβR2×PD-1 bispecific antibody, has the potential to be an effective treatment in microsatellite stable (MSS) colorectal cancerPlanned initiation of registrational program for INCA33890 in MSS colorectal cancer in 2026Maturing data for INCB161734, a KRAS G12D inhibitor, shows a favorable safety profile and evidence of clinical benefit in heavily pre-treated pancreatic ductal adenocarcinoma (PDAC) patientsIncyte will expand on the results from the oral presentations at an in-person and webcasted event on Sunday, October 19, 2025, from 1:30 – 3:00 p.m. EDT (7:30 – 9:00 p.m. CEST) Incyte (Nasdaq:INCY) announced the first clinical data evaluating its TGFβR2×PD-1 bispecific antibody (INCA33890) for patients with microsatellite stable (MSS) colorectal cancer; and its potent, selective and orally bioavailable KRAS G12D inhibitor (INCB161734) for patients with KRAS G12D mutations, specifically pancreatic ductal adenocarcinoma (PDAC). The data were

Corcept Presents ESMO 2025 Late-Breaker: Relacorilant Demonstrates Benefit in Patients with Platinum-Resistant Ovarian Cancer with Prior PARP Inhibitor Treatment19.10.2025 11:15:00 CEST | Press release

New data from pivotal Phase 3 ROSELLA trial reinforce relacorilant plus nab-paclitaxel improves progression-free and overall survival in patients with platinum-resistant ovarian cancer, with no need for biomarker selection – including in people who progressed while on or after taking a PARP inhibitor, a patient population with particularly poor prognosis Corcept expands BELLA trial to three study arms: (i) platinum-resistant ovarian cancer, (ii) platinum-sensitive ovarian cancer and (iii) endometrial cancer Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today shared new late-breaking data from its pivotal Phase 3 ROSELLA trial of relacorilant plus nab-paclitaxel in patients with platinum-resistant ovarian cancer at the European Society for Medical Oncology (ESMO) 2025 Annual

Deciphera Presents 2-Year Efficacy and Safety Results from MOTION Phase 3 Study of ROMVIMZA™ (vimseltinib) in Patients with Tenosynovial Giant Cell Tumor (TGCT) at the European Society for Medical Oncology Congress 202518.10.2025 13:00:00 CEST | Press release

– Vimseltinib demonstrated statistically significant and clinically meaningful benefit vs placebo in antitumor response – Ono Pharmaceutical Co., Ltd. (Headquarters: Osaka, Japan; President and COO: Toichi Takino; “Ono”), today announced the two-year efficacy and safety results from its MOTION Phase 3 study of vimseltinib in patients with TGCT in cases where surgical removal of the tumor is not an option will be presented as a poster during the 2025 European Society for Medical Oncology Congress (ESMO), taking place October 17-21 in Berlin, Germany. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20251018921529/en/ “These long-term Phase 3 MOTION results add to the established body of evidence supporting vimseltinib as a best-in-class treatment for TGCT,” said Matthew L. Sherman, M.D., Chief Medical Officer of Deciphera. “TGCT often causes debilitating pain, stiffness and impaired mobility and these results demonstrate the dura

ProAmpac Acquires International Paper’s Bag Converting Operations17.10.2025 16:09:00 CEST | Press release

ProAmpac, a global leader in flexible packaging and material science, has acquired the bag converting operations of International Paper (“IP”), a global leader in sustainable packaging. The acquisition expands ProAmpac’s converting capabilities, further advancing the company’s Fiberization of Packaging® strategy and enhancing its ability to deliver customized bag solutions for the grocery, convenience store, and quick-service restaurant markets. “Global demand for reliable, recyclable paper packaging continues to grow rapidly amid evolving consumer expectations and market trends redefining recyclability,” stated Greg Tucker, ProAmpac founder, vice chairman, and chief executive officer. “ProAmpac’s acquisition of IP’s bag operation supports our Fiberization of Packaging initiatives, helping us better serve customers by extending our expertise in material science to the US west coast with additional capabilities and redundancies,” continued Tucker. “IP’s bag business is strong, being bui

Pimicotinib Treatment Demonstrates Deep and Durable Tumor Responses and Continued Improvements in Pain and Function for Patients with TGCT17.10.2025 16:00:00 CEST | Press release

With median follow-up of 14.3 months, pimicotinib demonstrated increasing ORR over time, from 54% at Week 25 to 76.2%Global Phase 3 MANEUVER study demonstrated ongoing improvements in key secondary endpoints including pain and functionApplication for marketing authorization under review by China National Medical Products Administration (NMPA), with additional applications planned in the U.S. and other marketsNot intended for Canada-, UK- or US-based media Merck, a leading science and technology company, today announced the presentation of longer-term results from the global Phase 3 MANEUVER trial evaluating pimicotinib, an investigational colony stimulating factor-1 receptor (CSF-1R) inhibitor in development by Abbisko Therapeutics Co., Ltd., for the treatment of patients with tenosynovial giant cell tumor (TGCT). This latest analysis showed that, with a median follow-up of 14.3 months, the objective response rate (ORR) for people treated with pimicotinib from the beginning of the stud

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye